Načítá se...
EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is of great interest in human cancer. It has been shown to have a dual nature, as it can act as a gene repressor or activator. Studies have highlighted the various roles of EZH2 in the pathophysiology of multiple myeloma (MM). It...
Uloženo v:
| Vydáno v: | Biomark Res |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6286605/ https://ncbi.nlm.nih.gov/pubmed/30555699 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-018-0148-5 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|